(NASDAQ: NBP) Novabridge Biosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.69%.
Novabridge Biosciences's earnings in 2026 is -$46,269,000.On average, 5 Wall Street analysts forecast NBP's earnings for 2026 to be -$146,090,529, with the lowest NBP earnings forecast at -$244,466,113, and the highest NBP earnings forecast at -$41,797,018. On average, 5 Wall Street analysts forecast NBP's earnings for 2027 to be -$182,261,536, with the lowest NBP earnings forecast at -$275,674,553, and the highest NBP earnings forecast at -$83,594,036.
In 2028, NBP is forecast to generate -$203,704,069 in earnings, with the lowest earnings forecast at -$312,084,400 and the highest earnings forecast at -$89,166,971.